Earnings Feed
Start Free
Home/Filings/4/0001209191-23-046102
4//SEC Filing

Galimi Francesco 4

Accession 0001209191-23-046102

CIK 0001720580other
View on SEC.govCompany Profile

Filed

Aug 15, 8:00 PM ET

Accepted

Aug 16, 6:11 PM ET

Size

33.5 KB

Accession

0001209191-23-046102

Insider Transaction Report

Form 4
Period: 2023-08-14
Adicet Bio, Inc.ACET
Galimi Francesco
Chief Medical Officer
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-08-14−77,269→ 0 total
    Exercise: $16.11Exp: 2030-09-16→ Common Stock (77,269 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-08-14−73,964→ 0 total
    Exercise: $13.27Exp: 2031-01-12→ Common Stock (73,964 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-08-14+125,000→ 125,000 total
    Exercise: $2.14Exp: 2032-01-06→ Common Stock (125,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-08-14−117,200→ 0 total
    Exercise: $9.05Exp: 2033-01-23→ Common Stock (117,200 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-08-14−125,000→ 0 total
    Exercise: $15.52Exp: 2032-01-06→ Common Stock (125,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-08-14+113,652→ 113,652 total
    Exercise: $2.14Exp: 2029-10-15→ Common Stock (113,652 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-08-14+73,964→ 73,964 total
    Exercise: $2.14Exp: 2031-01-12→ Common Stock (73,964 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-08-14−113,652→ 0 total
    Exercise: $5.97Exp: 2029-10-15→ Common Stock (113,652 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-08-14+77,269→ 77,269 total
    Exercise: $2.14Exp: 2030-09-16→ Common Stock (77,269 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-08-14−26,625→ 0 total
    Exercise: $16.82Exp: 2031-02-11→ Common Stock (26,625 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-08-14+26,625→ 26,625 total
    Exercise: $2.14Exp: 2031-02-11→ Common Stock (26,625 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-08-14+117,200→ 117,200 total
    Exercise: $2.14Exp: 2033-01-23→ Common Stock (117,200 underlying)
Footnotes (8)
  • [F1]On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  • [F2]A total of 128,424 shares subject to an employee stock option were granted to the Reporting Person on September 15, 2020, with 25% of the shares subject to this option vested and exercisable on September 23, 2020, and the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 14,772 shares subject to this option.
  • [F3]The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
  • [F4]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
  • [F5]A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 6,036 shares subject to this option.
  • [F6]A total of 28,400 shares subject to an employee stock option were granted on February 12, 2023, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 1,775 shares subject to this option.
  • [F7]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
  • [F8]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Documents

1 file

Issuer

Adicet Bio, Inc.

CIK 0001720580

→
Entity typeother

Related Parties

1
  • filerCIK 0001823996

Filing Metadata

Form type
4
Filed
Aug 15, 8:00 PM ET
Accepted
Aug 16, 6:11 PM ET
Size
33.5 KB
View on SEC.gov